诚意药业：鱼油EPA软胶囊获批，海洋生物医药再添重磅单品

Core Viewpoint - Chengyi Pharmaceutical has successfully obtained the drug registration certificate for its EPA soft capsules, marking a significant step in the high-purity EPA formulation sector, which is expected to create a new blockbuster product for the company [1][3]. Company Summary - Chengyi Pharmaceutical's EPA soft capsules have received approval for use in lowering triglyceride levels in adult patients with severe hypertriglyceridemia [1]. - The company reported a substantial increase in net profit for the first half of 2025, with a year-on-year growth of 47.03% and 54.21%, reaching 112 million yuan and 111 million yuan respectively, driven by rising sales of joint-related medications [1]. - The successful approval of the EPA soft capsules positions Chengyi Pharmaceutical to leverage its integrated advantages in high-purity EPA raw materials and formulations [1][3]. Industry Summary - The market for lipid-regulating agents is expanding, driven by an aging population and lifestyle changes, leading to a rise in chronic diseases such as cardiovascular diseases and metabolic syndromes [2]. - The prevalence of hyperlipidemia among adults in China has increased from 18.6% in 2002 to 35.6% in 2020, indicating a growing health burden [2]. - The global lipid-lowering drug market reached $33.12 billion in 2023 and is projected to grow to approximately $46.58 billion by 2033, with China's sales of lipid-regulating agents exceeding 22 billion yuan in 2023 [2]. - Current mainstream lipid-lowering medications, primarily statins and fibrates, have significant side effects, creating a demand for safer long-term treatment options [3]. - The approval of Chengyi Pharmaceutical's high-purity EPA drug fills a gap in the domestic market, potentially capturing a share of the 20 billion yuan lipid-lowering drug market and becoming a new pillar of the company's performance [3].